Welcome to our dedicated page for Charming Medical SEC filings (Ticker: MCTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Charming Medical Limited (Nasdaq: MCTA) provides access to the company’s U.S. regulatory disclosures as it operates as a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. As a foreign private issuer with Class A ordinary shares listed on the Nasdaq Capital Market, Charming Medical Limited files registration statements and other documents with the U.S. Securities and Exchange Commission.
The company’s initial public offering was conducted pursuant to a registration statement on Form F-1 that was declared effective by the SEC. That filing, together with the related prospectus, describes the terms of the offering, the Class A ordinary shares, the over-allotment option granted to underwriters, and the company’s stated use of proceeds, including business and geographic expansion, potential strategic investments and acquisitions, research and development, and general working capital and corporate purposes.
On Stock Titan, this page is designed to surface Charming Medical Limited’s SEC filings as they become available from EDGAR, including registration statements and, over time, periodic and other reports required of a Nasdaq-listed issuer. AI-powered summaries help explain the key points of lengthy documents, highlight important sections, and clarify how specific disclosures relate to the company’s TCM-inspired women’s wellness services, Beauty Lab product line, and broader growth plans.
Users can review filings to understand the structure of Charming Medical Limited’s share capital, details of its offering, risk factors, and other regulatory information. As additional filings such as annual and interim reports or insider transaction reports are made, this page will provide a centralized view with AI-generated insights to make the technical language more accessible.
Charming Medical Limited reported a change in its board leadership. On March 27, 2026, independent director Ms. Josephine Yan Yeung resigned from the board to pursue other business commitments. The company stated her resignation was not due to any disagreement with its operations, policies, or procedures.
The board accepted and approved Ms. Yeung’s resignation on the same day. Charming Medical is actively identifying a suitable replacement and expects to fill the independent director vacancy by April 2, 2026, aiming to maintain continuity in its board oversight.
Kit Wong has filed a Schedule 13D disclosing a controlling stake in Charming Medical Ltd. She beneficially owns 10,350,360 Class A ordinary shares and 2,000,000 Class B ordinary shares, giving her approximately 91.65% of the company’s aggregate voting power.
The Class A shares carry one vote per share and the Class B shares carry twenty votes per share, based on 14,938,000 Class A and 2,000,000 Class B shares outstanding. Wong, the company’s CEO, director, and board chair, notes she is a pre-IPO shareholder and holds the securities with the intent to exercise control, and reports no transactions in the past sixty days and no specific additional plans beyond this control position.
Charming Medical Ltd director Yu Shu Tai Victor has filed an initial statement of beneficial ownership on Form 3. The filing does not report any insider stock transactions or list any derivative positions for this director at Charming Medical Ltd.
Charming Medical Ltd director and Chief Executive Officer Wong Kit Christine has filed an initial statement of ownership. She reports holding 10,350,360 Class A ordinary shares and 2,000,000 Class B ordinary shares, each with a par value of US$0.0001 per share.
These positions are reported as direct ownership, and the filing does not show any new purchases or sales, only the share balances following the reporting date.
Charming Medical Ltd filed an initial insider ownership report for its Chief Financial Officer, Cheung Ching Man